Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

A Multicenter Retrospective Review of Pediatric Leydig Cell Tumor of the Testis

Luckie, Taylor M., BS*; Danzig, Matthew, MD; Zhou, Shengmei, MD; Wu, Hao, MD, PhD*,§; Cost, Nicholas G., MD; Karaviti, Lefkothea, MD; Venkatramani, Rajkumar, MD, MS, FAAP*

Journal of Pediatric Hematology/Oncology: January 2019 - Volume 41 - Issue 1 - p 74–76
doi: 10.1097/MPH.0000000000001124
Clinical and Laboratory Observations

Leydig cell tumors (LCTs) are rare tumors arising from testosterone-producing Leydig cells. Although LCTs are usually benign, malignancy has been reported in 10% of cases in adults, and local recurrence or metachronous tumors of the contralateral testis have been described. Radical orchiectomy is the current standard of care. We report on 12 children with LCT at 3 institutions between 2000 and 2016. Presenting symptoms included precocious puberty, palpable testicular mass, and scrotal swelling. Radical orchiectomy was performed in 9 patients. Three patients were treated with enucleation. All patients were alive at last follow-up without evidence of local recurrence or metastasis.

*Rare Tumors Program, Texas Children’s Cancer Center, Baylor College of Medicine

§Department of Pathology and Immunology, Baylor College of Medicine and Texas Children’s Hospital

Division of Pediatric Endocrinology and Metabolism, Texas Children’s Hospital, Houston, TX

Department of Surgery, Division of Urology, University of Colorado School of Medicine, Aurora, CO

Department of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Los Angeles, CA

The authors declare no conflict of interest.

Reprints: Rajkumar Venkatramani, MD, MS, FAAP, Department of Pediatrics, Baylor College of Medicine, Texas Children’s Cancer Center, Texas Children’s Hospital, 6701 Fannin St., Suite 1510, Houston, TX 77030 (e-mail: raretumors@txch.org).

Received July 25, 2017

Accepted October 4, 2017

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.